COVID-19-CURE

Merck agrees to let other drug makers produce its COVID pill

Oct 27, 2021, 7:13 AM | Updated: 10:07 am
FILE  - In this undated file image provided by Merck & Co. shows their new antiviral medication...
FILE - In this undated file image provided by Merck & Co. shows their new antiviral medication. The pharmaceutical Merck has agreed to allow other drugmakers worldwide to make its COVID-19 treatment, the first pill that has been shown to be effective against the disease, in a move aimed at helping millions of people in poorer countries access to the drug. In a statement on Wednesday, Oct. 27, 2021, the U.N.-backed Medicines Patent Pool said it had signed a voluntary licensing agreement for molnupiravir with Merck and its partner Ridgeback Biotherapeutics. (Merck & Co. via AP, File)
(Merck & Co. via AP, File)

LONDON (AP) — Pharmaceutical company Merck agreed to allow other drugmakers to produce its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access to the potentially life-saving drug, a United Nations-backed public health organization said on Wednesday.

The Medicines Patent Pool said in a statement that it had signed a voluntary licensing agreement for molnupiravir with Merck and its partner Ridgeback Biotherapeutics.

The agreement will allow the Medicines Patent Pool to grant further licenses to qualified companies who are approved to make the drug. Neither drug maker will receive royalties under the agreement for as long as the World Health Organization deems COVID-19 to be global emergency. Molnupiravir is the first pill that has been shown to treat the disease.

Charles Gore, the executive director of the Medicines Patent Pool, said the early results for molnupiravir were “compelling” and that he hoped this first voluntary licensing agreement for a COVID-19 treatment would lead to others.

Despite repeated requests from governments and health officials, no vaccine makers have agreed to a similar deal. A hub set up by WHO in South Africa intended to share messenger RNA vaccine recipes and technologies has not enticed a single pharmaceutical to join.

Merck has requested its pill be licensed by both the U.S. Food and Drug Administration and the European Medicines Agency, decisions that could come within weeks.

Merck reported this month that molnupiravir cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.

An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on hospitals and helping to curb outbreaks in poorer countries with weak health care systems.

It would also bolster a two-pronged approach to the pandemic: treatment by way of medication and prevention, primarily through vaccinations.

The charity Doctors Without Borders welcomed the agreement Merck struck to share its COVID-19 pill, but said it didn’t go far enough.

“The license excludes key upper-middle-income countries like Brazil and China from its territory, where there are strong, established capacity to produce and supply antiviral medicines,” said Yuanqiong Hu, a senior legal and policy adviser at Doctors Without Borders, who called the deal “disappointing.”

Today’s Top Stories

COVID-19-Cure

covid pill...
Curt Gresseth

Utah doctor weighs in on new COVID-19 pill you can take at home

A University of Utah doctor specializing in infectious diseases weighs the pros and cons on a new pill taken at home to treat coronavirus.
1 day ago
(Tanner Davies receives a COVID-19 vaccination at a NOMI/TestUtah vaccination site in Lindon on Tue...
Paul Nelson

As omicron variant spreads, Utahns urged to get vaccine booster shots

With the spread of the omicron variant, Utahns are being urged to get a COVID-19 vaccine booster shot
7 days ago
COVID vaccination rates...
Heather Kelly

Utah is below the national average for COVID vaccination rates, here’s why

Utah is below the national average for COVID vaccination rates. High numbers of children in Utah are likely skewing the data. Officials encourage vaccination.
8 days ago
utah covid children...
Paul Nelson

Researchers believe ‘omicron’ variant will be in Utah, sooner or later

The Omicron variant doesn't have officials saying we should cancel Christmas plans, but masks and social distancing are still recommended.
11 days ago
SHORELINE, WA - NOVEMBER 03: A firefighter prepares pediatric doses of the Pfizer-BioNtech Covid-19...
MICHAELEEN DOUCLEFF NPR

Studies find evidence of ‘Superhuman’ immunity to COVID-19

In an article released by NPR, some scientists are reporting “superhuman immunity” present in defending against COVID-19. This is also known as “hybrid immunity.” The article explains that scientists have discovered that certain individuals are able to produce an extremely powerful immune response against SARS-CoV-2, the coronavirus responsible for COVID-19. These individuals produce very high […]
27 days ago
Pfizer COVID-19 pill...
MATTHEW PERRONE AP Health Writer

Pfizer says COVID-19 pill cut hospital, death risk by 90%

Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections. The company announced Friday it will soon ask the U.S. Food and Drug Administration and international regulators to authorize its pill, which is taken twice a day for five days.
1 month ago
Merck agrees to let other drug makers produce its COVID pill